Sandoz Expands Kundl Site Sterile Production
News Mar 12, 2013
Sandoz has officially opened its new facilities in Kundl, Austria, thereby expanding the production of sterile penicillins at the site significantly and creating 30 new jobs.
With the expansion, Kundl has added two new floors to its existing building and increased its powder facilities from 10 to 12 with a planned annual capacity of more than 150 million vials.
Approximately 190 million packs of medicinal products are distributed annually from the Kundl site to around 100 countries.
Kundl is Sandoz’s largest production site and one of the world's leading antibiotics manufacturers as well as the last remaining fully integrated penicillin producer in the western world. Currently 200 employees work in the sterile penicillins production.
The size of the two new floors is approximately 22,500 m³ which equates to about 22 single-family homes. Together with the current space of 26,300 m³, the site will be equivalent in size to 48 single-family homes.
Jeff George, Global Head of Sandoz, said: “Expanding our sterile production in Kundl demonstrates our focus on differentiated products and our commitment to Austria. The significant expansion of our sterile production will also play a major role in strengthening innovation at the Kundl site.”
"We have decided to expand our production of sterile penicillins due to strong worldwide demand for antibiotics. The additional lines increase security of supply for the market and allow us to respond quickly to changing needs in the fast-paced generics business.” said Ernst Meijnders, Chairman of the Executive Board of Sandoz GmbH in Austria.
The guests at the opening included local politicians, representatives from industry, Kundl village’s priest, Dr. Piotr Stachiewicz, as well as Tyrol’s Governor Günther Platter.
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Comments | 0 ADD COMMENT
3rd Annual Bioprocessing of Advanced Cellular Therapies
May 29 - May 30, 2018